Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome.
Saved in:
| Title: | Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome. |
|---|---|
| Authors: | Foran JM; Division of Hematology & Medical Oncology, Mayo Clinic Florida, Jacksonville, FL, USA. Electronic address: Foran.James@mayo.edu., Sanz GF; Department of Haematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Health Research Institute La Fe, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain., Watts JM; University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Brunner AM; Center for Leukemia, Massachusetts General Hospital, Boston, MA, USA., Fossard G; Service d'Hématologie Clinique, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France., Della Porta MG; Cancer Center IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy., Tsai XC; National Taiwan University Hospital, No. 7, Taipei, Taiwan., Garcia-Manero G; Section of MDS, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dimicoli-Salazar S; Hôpital Haut-Lévêque, Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Fletcher L; Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR, USA., Kim YJ; Acute Leukemia Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Font P; Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain., Alfonso-Piérola A; Hematology and Cell Therapy Service, Cancer Center Clínica Universidad de Navarra (CCUN), IdISNA, Pamplona, Spain., Alonso-Dominguez JM; Hospital Universitario Fundación Jiménez Díaz - IIS-FJD, Madrid, Spain., Benton C; Rocky Mountain Cancer Centers, US Oncology Network, Denver, CO, USA., Hong J; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea., Malcovati L; Department of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Mazure D; Department of Hematology, Ghent University Hospital, Ghent, Belgium., Lee JH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Yeh SP; Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan., Goursaud L; Department of Hematology, CHU LILLE, Lille, France., Barcellini W; Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Wu E; Roivant Sciences, New York, NY, USA., Corzo D; Roivant Sciences, New York, NY, USA., Kuida K; Hemavant Sciences, Basel, Switzerland., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. |
| Source: | Leukemia research [Leuk Res] 2025 Sep; Vol. 156, pp. 107735. Date of Electronic Publication: 2025 Jun 09. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
